touchONCOLOGY met with editorial board member Dr Paolo Ascierto at ESMO 2018 to discuss the recent developments in the treatment of advanced melanoma. In this expert interview, Dr Ascierto reviews some of the recent trials investigating various immunotherapy combinations, and how survival rates have increased over the last few years. However, the levels of toxicity in these combinations can be a barrier to treatment. Finally, he talks about what he feels are some of the most interesting data at this year’s ESMO congress: the KEYNOTE-022 trial, which is the first trial to compare an anti-programmed cell death protein 1 (pembrolizumab) + a BRAF inhibitor (dabrafenib) + a MEK inhibitor (trametinib) versus BRAF + MEK inhibition alone.
1. What have been the most significant recent developments in the treatment of melanoma? (0:11)
2. What are the current unmet needs and/or the challenges you face when treating patients? (2:17)
3. What developments are you most excited about in the area of melanoma over the next few years? (3:47)
4. Which presentations/data from the ESMO 2018 congress have interested you the most? (5:22)
Speaker disclosures: Paolo A Ascierto has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Immunotherapy
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 2)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 2 of his interview, part one can be viewed here. Questions 1. How can we mitigate the toxicities associated with CAR-T cell therapy? (0:05) 2. What is […]
IBRAHIM EL HOUSSIENY, EHA 2019 – CAR-T cells and manufacturing (Part 1)
Ibrahim El Houssieny joins us at the EHA annual meeting in Amsterdam to discuss the most important recent therapeutic advances and manufacturing of CAR-T cells. This is part 1 of his interview, part two can be viewed here. Questions 1. What have been the most exciting recent developments in CAR-T cell therapy? (0:05) 2. Which […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!